- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06262555
Novel Light Delivery Method for Performing Transbronchial Photodynamic Therapy for Peripheral Lung Cancer
Novel Light Delivery Method for Performing Transbronchial Photodynamic Therapy Ablation to Treat Peripheral Lung Cancer: A Second Phase Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main focus of this research is the development of an innovative photodynamic therapy (PDT) mode applied to peripheral lung tumors. Current treatments for lung tumors, including primary lung cancer or metastatic tumors to the lungs, involve surgery, chemotherapy (including targeted and immunotherapy), and radiation therapy. The choice of treatment depends on factors such as tumor size, invasion, genetic characteristics, and the overall health of the patient.
For early-stage peripheral lung tumors, there is a continuous effort to develop minimally invasive treatment modalities to replace current surgical methods. Techniques such as computed tomography-guided percutaneous or bronchoscopic-guided radiofrequency ablation (RFA), microwave ablation, and photodynamic therapy are actively under research and development. Photodynamic therapy utilizes special photosensitizing drugs selectively absorbed by cancer cells, followed by exposure to light of specific wavelengths, triggering a reaction that destroys cancer cells.
Although photodynamic therapy has been successful in treating early-stage central airway lung cancer or advanced tumors causing airway obstruction, it has limitations. The penetration of light is restricted, resulting in a treatment range of approximately 1.5 to 2 centimeters in diameter. Multiple guidance and light treatments are needed to cover the entire tumor, increasing the technical difficulty of the procedure.
Light travels in a straight line and undergoes penetration, absorption, and reflection when encountering tissue interfaces, limiting its penetration within tissues. Dr. Friedberg in the United States proposed a novel lighting mode in 2003, using materials with high refractive indices, such as mineral oil (refractive index approximately 1.47), to enable light conduction in the trachea and bronchi. However, mineral oil is harmful to lung tissue, causing severe complications if inadvertently inhaled into the airways.
In this study, Lipiodol, a contrast agent with a refractive index of 1.47, was considered as a potential alternative to mineral oil. Lipiodol is a mixture of poppy seed oil and iodine ions and is commonly used in lymphography or for embolization therapy of liver tumors. It has been used for years in clinical practice for bronchoscopic instillation as a means of visualizing and locating lung tumors.
Based on these considerations, the research team hypothesized that by using electromagnetic navigation bronchoscopy to instill Lipiodol into the proximal trachea of the lung segment containing the tumor, the tumor could be completely surrounded by Lipiodol. Subsequent light therapy in the proximal trachea would then illuminate the lung tissue containing Lipiodol, including the tumor tissue, supplying blood vessels, and lymphatic tissue, selectively killing tumor tissue and potential early micro-metastases.
The research team conducted preclinical trials using a pig model, confirming that Lipiodol could be instilled into the peripheral lung tumor location via bronchoscopy. Moreover, light therapy with the current energy settings (200 J/cm, 400 mW/cm, 500 seconds) in Lipiodol-injected lung tissue was shown to be safe.
A multi-center clinical trial in the United States (ClinicalTrials.gov Identifier: NCT02916745) explored PDT for peripheral lung tumors. Photofrin was intravenously injected 48 hours before treatment, and under the guidance of electromagnetic navigation bronchoscopy and bronchoscopic ultrasound, the light fiber was inserted into the tumor site for PDT with an energy setting of 200 J/cm, 400 mW/cm, 500 seconds. The trial, as of January 2019, included five patients with no reports of severe complications, indicating initial safety and feasibility. Building upon this trial and the team's proposed novel PDT lighting mode, a phase I human clinical trial was initiated in October 2021 and is ongoing until February 2022. Three cases have been treated, and the initial observations suggest safety and feasibility. One patient, unfortunately, succumbed to obstructive pneumonia six weeks after treatment due to rapid disease progression, but it was not considered a treatment-related complication.
Although the effectiveness of the treatment was not as anticipated, further clinical trials are needed to determine the optimal lighting dosage. In the ongoing trial (NCT02916745), two cases received multiple light treatments from different directions without significant complications. A case report by Dr. Allison demonstrated successful and complication-free bronchoscopic PDT with two light treatments 48 hours apart in a patient ineligible for standard treatments.
The next phase of clinical trials is proposed based on the team's 2022 single-light treatment trial, aiming to assess safety and efficacy using multiple light treatments in different directions and an additional dose 48 hours later. This study will serve as a reference for the minimum basic lighting dosage (NOAEL) and the possible effective dosage for future phase I clinical trials.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yei San Hsieh
- Phone Number: +886975061108
- Email: yeisanh@gmail.com
Study Contact Backup
- Name: Shu-Hsing Cheng
- Phone Number: 8411 886-3-3699721
- Email: tyghcrc@gmail.com
Study Locations
-
-
-
Taoyuan City, Taiwan, 320
- Recruiting
- Taoyuan General Hospital, Ministry of Health and Welfare
-
Contact:
- Yei-San Hsieh, MD
- Phone Number: +886-975061108
- Email: yeisanh@gmail.com
-
Principal Investigator:
- Yei-San Hsieh, Dr.
-
Sub-Investigator:
- Hwi-Lu Chang, Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients diagnosed with advanced or terminal malignant lung tumors (including primary lung cancer and lung metastases from other cancers).
- Patients who have failed standard treatments (surgery, radiotherapy, or first and second-line chemotherapy/immunotherapy/targeted therapy) or are unsuitable for standard treatments.
- Tumor size less than or equal to 3 cm, clearly assessable on chest computed tomography.
Patients capable of providing informed consent and willing to undergo regular follow-ups during the trial.
Exclusion Criteria:
- Diagnosis of small cell lung cancer or non-solid malignancies.
- Tumors located in the central part of the lungs.
- Previous radiation therapy to the treatment site.
- Abnormal blood biochemical values.
- Chemotherapy received within the past 4 weeks.
- Tumor invading major blood vessels.
- Allergy to porphyrins or porphyrin-related metabolites, or allergy to Lipiodol or iodine-containing contrast agents.
- Planning radical surgery for lung tumors within the next 90 days.
- Potential need for slit lamp ophthalmic examination within the next 30 days due to existing eye diseases.
- Inability to undergo bronchoscopy due to mental health conditions.
- Pregnancy, planning pregnancy, breastfeeding, or planning to breastfeed within the next 6 months.
- Previous photodynamic therapy within the past 1 month.
- Severe kidney or liver disease with abnormal function.
- Planning to participate in other cancer treatment clinical trials within the next 3 months.
- HIV-positive patients.
- Individuals deemed unsuitable for the trial by the principal investigator and the safety monitoring committee due to severe illnesses.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
Photophrin 2mg/kg 48 hours before treatment.
Navigational bronchoscope guide the catheter into the tumor and adjacent to the tumor and give lipiodol for light diffusion and give light 200J/cm from different angle
|
Transbronchial lung tumor ablation with Photodynamic therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical Feasibility
Time Frame: 3 days
|
Number of times photodynamic therapy was delivered into the tumor using navigational bronchoscopy for each subject
|
3 days
|
Technical Safety
Time Frame: 6 months
|
Events Incidence Indicating Safety of Novel Photodynamic Therapy The incidence of adverse events following Novel PDT will be presented as the primary safety indicator for this treatment.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor remission rate
Time Frame: 3 months
|
Tumor Response at 3 Months Post Photodynamic Therapy (PDT) From the start of treatment until 6 months post-treatment measured as per the Modified RECIST (Response Evaluation Criteria in Solid Tumors) Criteria
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yei San Hsieh, Taoyuan General Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TYGH111061
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on Transbronchial PDT peripheral lung tumor ablation
-
Qianfoshan HospitalNot yet recruitingPulmonary Nodule | Ablation
-
Zhongda HospitalRecruitingSafety | Ablation | Nalbuphine AllergyChina
-
University of Maryland, BaltimoreUniversity of Maryland Greenebaum Cancer CenterCompletedInfection | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
University of California, DavisSuspendedVertebral Compression Fracture | Facet Joint PainUnited States
-
National Cancer Institute (NCI)Active, not recruitingHairy Cell LeukemiaUnited States
-
Biosense Webster, Inc.CompletedParoxysmal Atrial FibrillationUnited States, France, Switzerland
-
Guang'anmen Hospital of China Academy of Chinese...National Natural Science Foundation of China; Special Project of National Traditional...Not yet recruitingCoronary Heart Disease | Unstable Angina | Chinese Herbal Medicine